Condition (MeSH)
Herpangina
ClinicalTrials.gov lists 8 trials for Herpangina or a narrower condition beneath it. Sinovac Biotech Co., Ltd has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Herpangina itself; the rest are tagged with a narrower condition beneath it.
When did Herpangina trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2023 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2013 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 8 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Herpangina trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Observational | 2 |
How many Herpangina trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 6 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Herpangina trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Sinovac Biotech Co., Ltd | 3 |
| Jiangsu Province Centers for Disease Control and Prevention | 1 |
Which publications cover Herpangina? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. | The New England journal of medicine | 2014 | Yes |
| Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. | Pediatrics | 2002 | Yes |
| Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. | JAMA | 2004 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.